TY - JOUR AU - Hergenhan, Anja AU - Steurer, Martina AU - Berger, Thomas M. PY - 2015/11/01 Y2 - 2024/03/29 TI - Gestational age-adapted oxygen saturation targeting and outcome of extremely low gestational age neonates (ELGANs) JF - Swiss Medical Weekly JA - Swiss Med Wkly VL - 145 IS - 4546 SE - Original article DO - 10.4414/smw.2015.14197 UR - https://smw.ch/index.php/smw/article/view/2097 SP - w14197 AB - <p><p>QUESTIONS UNDER STUDY: Optimal oxygen saturation (SpO<sub>2</sub>) targets for extremely low gestational age neonates (ELGANs, gestational age [GA] &lt;28 weeks) are unknown. Conflicting results from five recently published multicentre trials, which randomised ELGANs to high (91 to 95%) or low (85 to 89%) SpO<sub>2</sub> targets from birth up to a corrected GA of 36 weeks, prompted us to examine our experience with two different SpO<sub>2</sub>policies.</p> <p>METHODS: We retrospectively compared outcomes of two cohorts of ELGANs which were exposed to two different SpO<sub>2</sub> target policies adapted to the infants’ corrected GA. Between 1 January 2000 and 30 June 2007, SpO<sub>2</sub> targets were 85 to 95% at &lt;30 weeks and 88 to 97% at ≥30 weeks (high SpO<sub>2</sub> target cohort, n = 157). Between 1 July 2007 and 31 December 2011, SpO<sub>2</sub> targets were lowered to 80 to 90% at &lt;30 weeks, 85 to 95% between 30 and 34 weeks and finally 88 to 97% at ≥34 weeks (low SpO<sub>2</sub> target cohort, n = 84).</p> <p>RESULTS: There were no statistically significant differences between the high and low SpO<sub>2</sub> target cohorts in mortality rates (15.9 vs 17.9%, risk ratio [RR] 0.89; 95% confidence interval [CI] 0.50–1.60), incidences of severe retinopathy of prematurity (2.3 vs 0%, RR 3.68; 95% CI 0.19–70.3), or moderate/severe bronchopulmonary dysplasia (14.4 vs 21.1%, RR 0.68; 95% CI 0.37–1.26).</p> <p>CONCLUSIONS:Adapting SpO<sub>2</sub> targets to the advancing corrected GA seems safe and is associated with low incidences of short-term complications. Mortality rates did not vary with the two different SpO<sub>2</sub> target policies utilised and were comparable to those reported from recently published randomised controlled SpO<sub>2</sub> target trials.</p></p> ER -